HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

(19)

(11)

EP 3 814 360 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	06.11.2024 Bulletin 2024/45

(45)	Mention of the grant of the patent:
	02.10.2024 Bulletin 2024/40

(21)	Application number: 19737443.2

(22)	Date of filing: 25.06.2019

(51)

International Patent Classification (IPC):

C07D 495/04^(2006.01)
A61P 25/00^(2006.01)
A61P 25/28^(2006.01)
A61K 31/5025^(2006.01)
A61K 31/4985^(2006.01)
A61K 31/506^(2006.01)
A61K 31/438^(2006.01)

C07D 519/00^(2006.01)
A61P 25/14^(2006.01)
A61K 31/454^(2006.01)
A61K 31/439^(2006.01)
A61K 31/415^(2006.01)
A61K 31/497^(2006.01)
A61K 31/53^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	C07D 495/04; C07D 519/00; A61P 25/00; A61P 25/14; A61P 25/28

(86)	International application number:
	PCT/US2019/038900

(87)	International publication number:
	WO 2020/005882 (02.01.2020 Gazette 2020/01)

(54)	HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HETEROARYL VERBINDUNGEN ZUR BEHANDLUNG VON MORBUS HUNTINGTON COMPOSÉS HÉTÉROARYL POUR TRAITER LA MALADIE DE HUNTINGTON

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

27.06.2018 US 201862690605 P

(43)	Date of publication of application:
	05.05.2021 Bulletin 2021/18

(73)	Proprietor: PTC Therapeutics, Inc.
	Warren, NJ 07059 (US)

(72)	Inventors:
	CHEN, Guangming Bridgewater, NJ 08807 (US) BHATTACHARYYA, Anuradha Edison, NJ 08820 (US) JIANG, Yao Plainfield, NJ 07080 (US) KARP, Gary, Mitchell Princeton Junction, NJ 08550 (US) NARASIMHAN, Jana New York Avenue Scotch Plains, NJ 07076 (US) TURPOFF, Anthony Hillsborough, NJ 08844 (US) ZHANG, Nanjing Princeton, NJ 08540 (US)

(74)	Representative: V.O.
	P.O. Box 87930 2508 DH Den Haag 2508 DH Den Haag (NL)

(56)

References cited: :

WO-A1-2017/100726
WO-A2-2010/130934
US-B2- 8 563 550

WO-A1-2019/165073
GB-A- 1 047 935

CHLOÉ COPIN ET AL: "S N Ar versus Buchwald-Hartwig Amination/Amidation in the Imidazo[2,1- b ][1,3,4]thiadiazole Series : S N Ar versus Buchwald-Hartwig Amination/Amidation", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2015, no. 31, 29 September 2015 (2015-09-29), DE, pages 6932 - 6942, XP055583698, ISSN: 1434-193X, DOI: 10.1002/ejoc.201500977
PATEL HARUN M ET AL: "2,5,6-Trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: Search for antihyperlipidemic agents", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 65, 18 April 2013 (2013-04-18), pages 119 - 133, XP028677323, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2013.04.020
MAZZONE G ET AL: "Sintesi e valutazione biologica preliminare di imidazo[2,1-b]-1,3-4-tiadiazoli-2,6-diarilsostituti", FARMACO, EDIZIONE SCIENTIFICA, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 39, no. 7, 1 January 1984 (1984-01-01), pages 585 - 598, XP009514978, ISSN: 0430-0920
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 February 2018 (2018-02-22), XP002793334, Database accession no. 2178867-25-7
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 25 September 2017 (2017-09-25), XP002793335, Database accession no. 2130694-60-7
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 24 September 2017 (2017-09-24), XP002793336, Database accession no. 2130300-22-8
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 September 2017 (2017-09-18), XP002793337, Database accession no. 2128311-64-6
FASCIO MIRTA L ET AL: "Synthesis and antiviral activity of some imidazo[1,2-b][1,3,4]thiadiazole carbohydrate derivatives", CARBOHYDRATE RESEARCH, vol. 480, 21 May 2019 (2019-05-21), pages 61 - 66, XP085709839, ISSN: 0008-6215, DOI: 10.1016/J.CARRES.2019.05.003

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).